L-FMAC | CAS#848087-71-8 | bioactive chemical

MedKoo Cat#: 597079 | Name: L-FMAC

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-FMAC is a bioactive chemical.

Chemical Structure

L-FMAC

CAS#848087-71-8

Theoretical Analysis

MedKoo Cat#: 597079

Name: L-FMAC

CAS#: 848087-71-8

Chemical Formula: C10H14FN3O4

Exact Mass: 259.0968

Molecular Weight: 259.24

Elemental Analysis: C, 46.33; H, 5.44; F, 7.33; N, 16.21; O, 24.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L-FMAC; L FMAC; LFMAC;

IUPAC/Chemical Name

4-amino-1-((2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidin-2(1H)-one

InChi Key

QZZJZXAWLQYJFK-XQXXSGGOSA-N

InChi Code

InChI=1S/C10H14FN3O4/c1-4-2-14(10(17)13-8(4)12)9-6(11)7(16)5(3-15)18-9/h2,5-7,9,15-16H,3H2,1H3,(H2,12,13,17)/t5-,6+,7-,9-/m0/s1

SMILES Code

O=C1N=C(N)C(C)=CN1[C@@H]2[C@H](F)[C@H]([C@H](CO)O2)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L-FMAC is a bioactive chemical.

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 259.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Park SH, Park KS, Kim NH, Cho JY, Koh MS, Lee JH. Clevudine Induced Mitochondrial Myopathy. J Korean Med Sci. 2017 Nov;32(11):1857-1860. doi: 10.3346/jkms.2017.32.11.1857. PubMed PMID: 28960041; PubMed Central PMCID: PMC5639069. 2: He L, Liu X, Zhao Y, Zhang S, Jiang Y, Wang X, Yang Z. Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Dis Markers. 2017;2017:7075935. doi: 10.1155/2017/7075935. Epub 2017 Mar 15. Review. PubMed PMID: 28396612; PubMed Central PMCID: PMC5370486. 3: Jadvar H, Park R, Yap LP, Chen K, Hughes L, Conti P. Effect of Androgen on Normal Biodistribution of [(18)F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Res. 2017 Feb;37(2):475-479. PubMed PMID: 28179292; PubMed Central PMCID: PMC5404414. 4: McHugh CI, Lawhorn-Crews JM, Modi D, Douglas KA, Jones SK, Mangner TJ, Collins JM, Shields AF. Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: (18)F-FAU, (18)F-FMAU, and (18)F-FLT. Cancer Imaging. 2016 Oct 17;16(1):34. PubMed PMID: 27751167; PubMed Central PMCID: PMC5067904. 5: Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG; Antiviral Resistance Study Group. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. Gut Liver. 2017 Jan 15;11(1):129-135. doi: 10.5009/gnl15597. PubMed PMID: 27538443; PubMed Central PMCID: PMC5221870. 6: Shin JH, Kwon HJ, Jang HR, Lee JE, Gwak GY, Huh W, Jung SH, Lee JH, Kim YG, Kim DJ, Oh HY. Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine (Baltimore). 2016 Jan;95(1):e2400. doi: 10.1097/MD.0000000000002400. PubMed PMID: 26735542; PubMed Central PMCID: PMC4706262. 7: Clark DN, Hu J. Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development. Antiviral Res. 2015 Nov;123:132-7. doi: 10.1016/j.antiviral.2015.09.011. Epub 2015 Sep 25. Review. PubMed PMID: 26408354; PubMed Central PMCID: PMC4639421. 8: Ahn SH, Kim DH, Lee AR, Kim BK, Park YK, Park ES, Ahn SH, Shin GC, Park S, Kang HS, Rhee JK, Yang SI, Chong Y, Kim KH. Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. PLoS One. 2015 Aug 31;10(8):e0136728. doi: 10.1371/journal.pone.0136728. eCollection 2015. PubMed PMID: 26322642; PubMed Central PMCID: PMC4556173. 9: Jadvar H, Chen K, Ukimura O. Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clin Nucl Med. 2015 Aug;40(8):e426-8. doi: 10.1097/RLU.0000000000000814. PubMed PMID: 26018690; PubMed Central PMCID: PMC4494895. 10: McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest. 2015 May;125(5):1815-26. doi: 10.1172/JCI77326. Epub 2015 Mar 30. PubMed PMID: 25822024; PubMed Central PMCID: PMC4463193. 11: Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014 Aug 13;14:439. doi: 10.1186/1471-2334-14-439. PubMed PMID: 25125320; PubMed Central PMCID: PMC4148928. 12: Tak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, Kim DY, Yoo BC. A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients. Hepatol Int. 2014 May 25;8(3):375-81. doi: 10.1007/s12072-014-9537-5. eCollection 2014 Jul. PubMed PMID: 25101150; PubMed Central PMCID: PMC4116600. 13: van Bömmel F, Berg T. Antiviral therapy of chronic hepatitis B. Intervirology. 2014;57(3-4):171-80. doi: 10.1159/000360945. Epub 2014 Jul 15. PubMed PMID: 25034485. 14: Menéndez-Arias L, Álvarez M, Pacheco B. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014 Oct;8:1-9. doi: 10.1016/j.coviro.2014.04.005. Epub 2014 May 9. Review. PubMed PMID: 24814823. 15: Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014 Sep;29(9):1699-705. doi: 10.1111/jgh.12612. PubMed PMID: 24730702. 16: Cho JY, Paik YH, Sohn W, Cho HC, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014 Dec;63(12):1943-50. doi: 10.1136/gutjnl-2013-306409. Epub 2014 Mar 10. PubMed PMID: 24615378. 17: Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014 Mar;29(3):428-34. doi: 10.1111/jgh.12499. Review. PubMed PMID: 24372662. 18: Chan PC, Wu CY, Chang WT, Lin CY, Tseng YL, Liu RS, Alauddin MM, Lin WJ, Wang HE. Monitoring tumor response with [18F]FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment. Nucl Med Biol. 2013 Nov;40(8):1035-42. doi: 10.1016/j.nucmedbio.2013.07.003. Epub 2013 Aug 19. PubMed PMID: 23969084. 19: Kim BK, Ko SY, Kwon SY, Park E, Kim JH, Choe WH, Lee CH. Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients. Hepat Mon. 2013 Apr 1;13(4):e6056. doi: 10.5812/hepatmon.6056. Print 2013 Apr. PubMed PMID: 23805155; PubMed Central PMCID: PMC3693539. 20: Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013 Sep;57(9):4181-9. doi: 10.1128/AAC.00599-13. Epub 2013 Jun 17. Erratum in: Antimicrob Agents Chemother. 2013 Nov;57(11):5788. PubMed PMID: 23774432; PubMed Central PMCID: PMC3754288.